Whether EIKANCE 0.01% Atropine Sulfate Eye Drops can be used for a long time and the safety risk analysis of long-term use

EIKANCE 0.01% Atropine Sulfate Eye Drops is a low-concentration atropine eye drop, mainly used to delay the progression of myopia in children. Its mechanism of action is by antagonizing parasympathetic nerve signals in the eye, reducing the growth rate of the anterior and posterior axis of the eyeball, thereby delaying the development of myopia. Compared with high-concentration atropine, 0.01%low-concentration eye drops are less likely to cause obvious mydriasis or accommodation disorders while controlling the progression of myopia. Therefore, they have been widely used clinically for myopia intervention in children in recent years.

Regarding long-term use, studies have shown that0.01% Atropine eye drops can be used continuously for several years in children's myopia intervention. Usually the effect is relatively stable when used within 3 to 5 years, and can significantly delay the increase in myopia. Clinical guidelines recommend starting use during the period of rapid progression of myopia in children, and regularly evaluating the efficacy and eye health under the guidance of a doctor, and adjusting the treatment plan or temporarily discontinuing the drug if necessary. Long-term use is not indefinitely safe, so close follow-up is still required.

Major safety risks with long-term use include ocular irritation, conjunctival hyperemia, mild photophobia or symptoms related to mydriasis. When used at low concentrations (0.01%), these adverse effects are generally mild and tolerable. A small number of patients may experience local allergic reactions or dry eye symptoms, which require prompt evaluation and corresponding nursing measures. In addition, long-term use of atropine eye drops may affect children's accommodation function, but low-concentration preparations have minimal impact on vision accommodation and generally do not cause significant impairment in daily vision.

In terms of safety management, long-term use of EIKANCE should follow the principle of individualization. Parents and doctors need to regularly monitor children's vision changes, axial length and intraocular pressure to ensure that the treatment course is scientific and reasonable; at the same time, pay attention to observing adverse reactions and keeping medication records. Overall, 0.01%Atropine sulfate eye drops can be used for a long time in the control of myopia in children with low risks, but the medication needs to be standardized under professional guidance to achieve maximum efficacy and minimum safety risks.

Keyword tags: Atropine sulfate eye drops, children's myopia, long-term use, safety, axial control

Reference materials:https://www.fda.gov/drugs